Pandemrix regulatory update

EMA's CHMP said it has no new concerns related to the risk of narcolepsy in patients treated with GlaxoSmithKline's Pandemrix swine influenza A (H1N1) vaccine after reviewing preliminary results from the Finnish National Institute of Health and Welfare. CHMP said the evidence is insufficient to allow conclusions to be drawn regarding immunological responses triggered by different pandemic flu vaccines, including Pandemrix. The committee said Pandemrix was approved in September 2009, but is not currently available in the EU. ...